Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selma Ugurel

Showing results (41-50 of 264) with videos related to

Pageof 27
Sort By:
Der Pathologe|March 25, 2020
[Malignant melanoma]Georg Lodde, Lisa Zimmer, Elisabeth Livingstone, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim MelanomIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
International Journal of Cancer|July 19, 2002
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patientsVera Rebmann, Selma Ugurel, Wolfgang Tilgen, et al.
European Journal of Dermatology : EJD|August 29, 2006
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanomaAdina Thoelke, Hans-Peter Schmid, Robert Figl, et al.
Cancer Treatment and Research|October 24, 2007
New promises in the adjuvant, and palliative treatment of melanomaAxel Hauschild, Dirk Schadendorf, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update on the clinical use of kinase inhibitors in melanomaIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
The Interplay between Metabolic Adaptations and Diet in Cancer ImmunotherapyLena Espelage, Natalie Wagner, Jan-Malte Placke, et al.
International Journal of Cancer|June 16, 2005
Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanomaSelma Ugurel, Nellie Bell, Antje Sucker, et al.
Deutsches Arzteblatt International|March 16, 2012
Cutaneous side effects of new antitumor drugs: clinical features and managementRalf Gutzmer, Andreas Wollenberg, Selma Ugurel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 23, 2009
Cutaneous metastases as the first clinical sign of metastatic gastric carcinomaLidia Frey, Claudia Vetter-Kauczok, Anja Gesierich, et al.
Pageof 27

Showing results (41-50 of 264) with videos related to

Sort By:
Pageof 27
Der Pathologe|March 25, 2020
[Malignant melanoma]Georg Lodde, Lisa Zimmer, Elisabeth Livingstone, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim MelanomIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
International Journal of Cancer|July 19, 2002
Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patientsVera Rebmann, Selma Ugurel, Wolfgang Tilgen, et al.
European Journal of Dermatology : EJD|August 29, 2006
Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanomaAdina Thoelke, Hans-Peter Schmid, Robert Figl, et al.
Cancer Treatment and Research|October 24, 2007
New promises in the adjuvant, and palliative treatment of melanomaAxel Hauschild, Dirk Schadendorf, Claus Garbe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 6, 2017
Update on the clinical use of kinase inhibitors in melanomaIoana Cosgarea, Cathrin Ritter, Jürgen C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
The Interplay between Metabolic Adaptations and Diet in Cancer ImmunotherapyLena Espelage, Natalie Wagner, Jan-Malte Placke, et al.
International Journal of Cancer|June 16, 2005
Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanomaSelma Ugurel, Nellie Bell, Antje Sucker, et al.
Deutsches Arzteblatt International|March 16, 2012
Cutaneous side effects of new antitumor drugs: clinical features and managementRalf Gutzmer, Andreas Wollenberg, Selma Ugurel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 23, 2009
Cutaneous metastases as the first clinical sign of metastatic gastric carcinomaLidia Frey, Claudia Vetter-Kauczok, Anja Gesierich, et al.
Pageof 27